1. Home
  2. HURA vs ACB Comparison

HURA vs ACB Comparison

Compare HURA & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • ACB
  • Stock Information
  • Founded
  • HURA 2009
  • ACB 2013
  • Country
  • HURA United States
  • ACB Canada
  • Employees
  • HURA N/A
  • ACB N/A
  • Industry
  • HURA
  • ACB Pharmaceuticals and Biotechnology
  • Sector
  • HURA
  • ACB Health Care
  • Exchange
  • HURA Nasdaq
  • ACB Nasdaq
  • Market Cap
  • HURA 246.9M
  • ACB 225.0M
  • IPO Year
  • HURA N/A
  • ACB N/A
  • Fundamental
  • Price
  • HURA $4.39
  • ACB $4.28
  • Analyst Decision
  • HURA
  • ACB Hold
  • Analyst Count
  • HURA 0
  • ACB 1
  • Target Price
  • HURA N/A
  • ACB N/A
  • AVG Volume (30 Days)
  • HURA 668.3K
  • ACB 694.1K
  • Earning Date
  • HURA 02-15-2025
  • ACB 02-06-2025
  • Dividend Yield
  • HURA N/A
  • ACB N/A
  • EPS Growth
  • HURA N/A
  • ACB N/A
  • EPS
  • HURA N/A
  • ACB N/A
  • Revenue
  • HURA N/A
  • ACB $219,835,671.00
  • Revenue This Year
  • HURA N/A
  • ACB $22.14
  • Revenue Next Year
  • HURA N/A
  • ACB $7.12
  • P/E Ratio
  • HURA N/A
  • ACB N/A
  • Revenue Growth
  • HURA N/A
  • ACB 13.15
  • 52 Week Low
  • HURA $2.84
  • ACB $2.84
  • 52 Week High
  • HURA $14.60
  • ACB $9.35
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • ACB 37.54
  • Support Level
  • HURA N/A
  • ACB $4.17
  • Resistance Level
  • HURA N/A
  • ACB $4.53
  • Average True Range (ATR)
  • HURA 0.00
  • ACB 0.20
  • MACD
  • HURA 0.00
  • ACB 0.01
  • Stochastic Oscillator
  • HURA 0.00
  • ACB 16.21

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About ACB Aurora Cannabis Inc.

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.

Share on Social Networks: